SciSparc Ltd. SPRC announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel.
What Happened
The Israeli specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system enrolled the first patient in March to its clinical trial assessing the efficacy and safety of its cannabidiol (CBD)– based drug for the treatment of children with autism spectrum disorder.
The double-blind, randomized and placebo-controlled trial uses SciSparc’s proprietary SCI-210, a combination of CBD and CannAmide– the company’s Palmitoylethanolamide – which is designed to alleviate ASD symptoms. The trial was designed in consultation with the National Autism Research Center.
The company signed an agreement with Israel's manufacturer and distributor of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., to supply its CBD-rich oil from Cannbit strains to be used as part of SCI-210 treatment, last year.
Read Also: Cannabis & Children Autism: New Study Claims CBDA Can Help With Behavioral Issues In Kids With ASD
Why It Matters
"People of all genders, ethnicities and economic backgrounds can be diagnosed with ASD," Oz Adler, SciSparc's CEO said. "Although ASD can be a lifelong disorder, treatments and services can improve a person's symptoms and daily functioning. Consistent with our mission of improving people's lives, we are happy with the ongoing pace of enrollment in the SCI-210 trial and expect that this study will generate new scientific data so that others may be better helped in the future."
What's Next
The company plans to enroll 60 subjects between the ages of five and eighteen for twenty weeks, to assess how SCI-210 therapy compares to standard CBD monotherapy in managing symptoms of ASD.
SciSparc seeks to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.
Now read:
SPRC Price Action
SciSparc’s shares traded 0.8333% higher at $0.4235 per share at the time of writing on Tuesday morning.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.